Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.

MLA

Mallalieu, Navita L., et al. “Intravenous Dosing of Tocilizumab in Patients Younger than Two Years of Age with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Phase 1 Clinical Trial.” Pediatric Rheumatology, vol. 17, no. 1, Aug. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s12969-019-0364-z.

APA

Mallalieu, N. L., Wimalasundera, S., Hsu, J. C., Douglass, W., Wells, C., Penades, I. C., Cuttica, R., Huppertz, H.-I., Joos, R., Kimura, Y., Milojevic, D., Rosenkranz, M., Schikler, K., Constantin, T., & Wouters, C. (2019). Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology, 17(1), N.PAG. https://doi.org/10.1186/s12969-019-0364-z

Chicago

Mallalieu, Navita L., Sunethra Wimalasundera, Joy C. Hsu, Wendy Douglass, Chris Wells, Inmaculada Calvo Penades, Ruben Cuttica, et al. 2019. “Intravenous Dosing of Tocilizumab in Patients Younger than Two Years of Age with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Phase 1 Clinical Trial.” Pediatric Rheumatology 17 (1): N.PAG. doi:10.1186/s12969-019-0364-z.